Adaptive Biotechnologies Corporation

MUN:1HM Stock Report

Market Cap: €906.7m

Adaptive Biotechnologies Management

Management criteria checks 2/4

Adaptive Biotechnologies' CEO is Chad Robins, appointed in Sep 2009, has a tenure of 15.25 years. total yearly compensation is $8.90M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 1.23% of the company’s shares, worth €11.15M. The average tenure of the management team and the board of directors is 6.3 years and 8.9 years respectively.

Key information

Chad Robins

Chief executive officer

US$8.9m

Total compensation

CEO salary percentage7.4%
CEO tenure15.3yrs
CEO ownership1.2%
Management average tenure6.3yrs
Board average tenure8.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chad Robins's remuneration changed compared to Adaptive Biotechnologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$195m

Jun 30 2024n/an/a

-US$213m

Mar 31 2024n/an/a

-US$215m

Dec 31 2023US$9mUS$663k

-US$225m

Sep 30 2023n/an/a

-US$196m

Jun 30 2023n/an/a

-US$191m

Mar 31 2023n/an/a

-US$195m

Dec 31 2022US$9mUS$658k

-US$200m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$229m

Dec 31 2021US$9mUS$639k

-US$207m

Sep 30 2021n/an/a

-US$190m

Jun 30 2021n/an/a

-US$171m

Mar 31 2021n/an/a

-US$155m

Dec 31 2020US$7mUS$597k

-US$146m

Sep 30 2020n/an/a

-US$122m

Jun 30 2020n/an/a

-US$99m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$3mUS$493k

-US$70m

Sep 30 2019n/an/a

-US$62m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$3mUS$423k

-US$46m

Compensation vs Market: Chad's total compensation ($USD8.90M) is above average for companies of similar size in the German market ($USD1.46M).

Compensation vs Earnings: Chad's compensation has increased whilst the company is unprofitable.

CEO

Chad Robins (50 yo)

15.3yrs

Tenure

US$8,904,267

Compensation

Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...

Leadership Team

NamePositionTenureCompensationOwnership
Chad Robins
Co-Founder15.3yrsUS$8.90m1.23%
€ 11.2m
Julie Rubinstein
President & COO6.8yrsUS$2.97m0.32%
€ 2.9m
Harlan Robins
Co-Founder & Chief Scientific Officer15.3yrsUS$8.61m0.69%
€ 6.3m
Sharon Benzeno
Chief Commercial Officer of Immune Medicine6.8yrsUS$2.88m0.22%
€ 2.0m
Christopher Carlson
Founderno datano datano data
Kyle Piskel
VP, CFO & Principal Accounting Officer3.2yrsUS$1.66m0.10%
€ 948.2k
Karina Calzadilla
Vice President of Investor Relationsno datano datano data
Francis Lo
Chief People Officer5.7yrsno data0.17%
€ 1.6m
Susan Bobulsky
Chief Commercial Officer of MRD4.3yrsno data0.17%
€ 1.6m
Mary Lancelotta
Senior Vice President of MRD BioPharma1.3yrsno datano data

6.3yrs

Average Tenure

50yo

Average Age

Experienced Management: 1HM's management team is seasoned and experienced (6.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chad Robins
Co-Founder15.3yrsUS$8.90m1.23%
€ 11.2m
Peter Neupert
Lead Independent Director11yrsUS$355.00k0.093%
€ 847.7k
H. Parker
Member of Corporate Advisory Boardno datano datano data
Michelle Griffin
Independent Director5.8yrsUS$330.00k0.035%
€ 319.2k
Robert Hershberg
Independent Director11.8yrsUS$325.00k0.051%
€ 466.8k
Michael Pellini
Independent Director6.8yrsUS$310.00k0.037%
€ 333.6k
Carol Gallagher
Member of Corporate Advisory Boardno datano datano data
Craig Weissman
Member of Corporate Advisory Boardno datano datano data
Graham Allen
Member of Corporate Advisory Boardno datano datano data
Matthew Kahn
Member of Corporate Advisory Boardno datano datano data
Katey Owen
Independent Director3.8yrsUS$310.00k0.038%
€ 344.8k

8.9yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 1HM's board of directors are considered experienced (8.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 00:13
End of Day Share Price 2024/12/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adaptive Biotechnologies Corporation is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Derik de BruinBofA Global Research
Mark MassaroBTIG
Daniel LeonardCredit Suisse